EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin

Tatsuro Hitsumoto, Osamu Tsukamoto iD, Ken Matsuoka, Junjun Li iD, Li Liu, Yuki Kuramoto iD, Shuichiro Higo iD, Shou Ogawa, Noboru Fujino, Shohei Yoshida, Hidetaka Kioka iD, Hisakazu Kato und 19 weitere

Circulation · 2023

DOI: 10.1161/circulationaha.122.062885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, 2023. Verfasst von Tatsuro Hitsumoto und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Suita, Osaka, Japan (T.H., O.T., K.M., H. Kiok…. Hauptthemen laut MEDLINE: Heart Failure, Systolic, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiac-specific myosin light chain kinase (cMLCK), encoded by MYLK3 , regulates cardiac contractility through phosphorylation of ventricular myosin regulatory light chain. However, the pathophysiological and therapeutic implications of cMLCK in human heart failure remain unclear. We aimed to investigate whether cMLCK dysregulation causes cardiac dysfunction and whether the restoration of cMLCK could be a novel myotropic therapy for systolic heart failure.

Methods

We generated the knock-in mice ( Mylk3 +/fs and Mylk 3 fs/fs ) with a familial dilated cardiomyopathy–associated MYLK3 frameshift mutation ( MYLK3 +/fs ) that had been identified previously by us (c.1951-1G>T; p.P639Vfs*15) and the human induced pluripotent stem cell–derived cardiomyocytes from the carrier of the mutation. We also developed a new small-molecule activator of cMLCK (LEUO-1154).

Results

Both mice ( Mylk3 +/fs and Mylk 3 fs/fs ) showed reduced cMLCK expression due to nonsense-mediated messenger RNA decay, reduced MLC2v (ventricular myosin regulatory light chain) phosphorylation in the myocardium, and systolic dysfunction in a cMLCK dose–dependent manner. Consistent with this result, myocardium from the mutant mice showed an increased ratio of cardiac superrelaxation/disordered relaxation states that may contribute to impaired cardiac contractility. The phenotypes observed in the knock-in mice were rescued by cMLCK replenishment through the AAV9_ MYLK3 vector. Human induced pluripotent stem cell–derived cardiomyocytes with MYLK3 +/fs mutation reduced cMLCK expression by 50% and contractile dysfunction, accompanied by an increased superrelaxation/disordered relaxation ratio. CRISPR-mediated gene correction, or cMLCK replenishment by AAV9_ MYLK3 vector, successfully recovered cMLCK expression, the superrelaxation/disordered relaxation ratio, and contractile dysfunction. LEUO-1154 increased human cMLCK activity ≈2-fold in the V max for ventricular myosin regulatory light chain phosphorylation without affecting the K m . LEUO-1154 treatment of human induced pluripotent stem cell–derived cardiomyocytes with MYLK3 +/fs mutation restored the ventricular myosin regulatory light chain phosphorylation level and superrelaxation/disordered relaxation ratio and improved cardiac contractility without affecting calcium transients, indicating that the cMLCK activator acts as a myotrope. Finally, human myocardium from advanced heart failure with a wide variety of causes had a significantly lower MYLK3 / PPP1R12B messenger RNA expression ratio than control hearts, suggesting an altered balance between myosin regulatory light chain kinase and phosphatase in the failing myocardium, irrespective of the causes. Conclusions: cMLCK dysregulation contributes to the development of cardiac systolic dysfunction in humans. Our strategy to restore cMLCK activity could form the basis of a novel myotropic therapy for advanced systolic heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Failure, SystolicInduced Pluripotent Stem CellsHumansMiceAnimalsMyosin-Light-Chain KinasePhosphorylationMyosin Light ChainsMyocardiumMyocytes, CardiacMyocardial ContractionRNA, MessengerCardiac Myosins

Stichwörter der Autor:innen

cardiac myosinleftmyosin light chain kinasephosphorylationventricular dysfunction

Substanzen

Myosin-Light-Chain KinaseMyosin Light ChainsRNA, MessengerCardiac Myosins

Autor:innen und Institutionen

  • Department of Medical Biochemistry, Osaka University Graduate School of Medicine/Frontier Biosciences, Suita, Osaka, Japan (T.H., O.T., K.M., H. Kioka, H. Kato, H.H., Y.S., C.O., H.I., J.H., K.U., T.S., S.N., S.T.).
  • Department of Cardiovascular Surgery (J.L., L.L.), Osaka University Graduate School of Medicine. Suita, Osaka, Japan.
  • Department of Cardiology (Y.K., S.H., S.O., H. Kioka, HY.H., S.N., Y.A., Y.S.), Osaka University Graduate School of Medicine. Suita, Osaka, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University. Kanazawa, Ishikawa, Japan (N.F., S.Y., M.T.).
  • Department of Genomic Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.A.).
  • Department of Internal Medicine, Meiji University of Integrative Medicine, Nantan, Kyoto, Japan (H.A.).

ORCID-Profile: Osamu Tsukamoto, Junjun Li, Yuki Kuramoto, Shuichiro Higo, Hidetaka Kioka, Hideyuki Hakui, Chisato Okamoto, Yoshihiro Asano, Yasushi Sakata

Zitieren

APA

Hitsumoto, T., Tsukamoto, O., Matsuoka, K., Li, J., Liu, L., Kuramoto, Y., Higo, S., Ogawa, S., Fujino, N., Yoshida, S., Kioka, H., Kato, H., Hakui, H., Saito, Y., Okamoto, C., Inoue, H., Hyejin, J., Ueda, K., Segawa, T., …, & Takashima, S. (2023). Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin. Circulation. https://doi.org/10.1161/circulationaha.122.062885

Vancouver

Hitsumoto T, Tsukamoto O, Matsuoka K, Li J, Liu L, Kuramoto Y, et al. Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin. Circulation. 2023. doi:10.1161/circulationaha.122.062885

BibTeX
@article{Hitsumoto2023,
  author = {Hitsumoto, Tatsuro and Tsukamoto, Osamu and Matsuoka, Ken and Li, Junjun and Liu, Li and Kuramoto, Yuki and Higo, Shuichiro and Ogawa, Shou and Fujino, Noboru and Yoshida, Shohei and Kioka, Hidetaka and Kato, Hisakazu and Hakui, Hideyuki and Saito, Yuki and Okamoto, Chisato and Inoue, Hijiri and Hyejin, Jo and Ueda, Kyoko and Segawa, Takatsugu and Nishimura, Shunsuke and Asano, Yoshihiro and Asanuma, Hiroshi and Tani, Akiyoshi and Imamura, Riyo and Komagawa, Shinsuke and Kanai, Toshio and Takamura, Masayuki and Sakata, Yasushi and Kitakaze, Masafumi and Haruta, Jun-Ichi and Takashima, Seiji},
  title = {Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin},
  journal = {Circulation},
  year = {2023},
  doi = {10.1161/circulationaha.122.062885}
}
Kostenlos starten →